Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

Karolinska Institute

Status: Completed

Conditions: Allergic Asthma

Treatments: Drug: Single corticosteroid inhalers and Singulair

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00421018

20050166

Details and patient eligibility

About

The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma

Enrollment: 187 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-64
• Clinical diagnosis of Asthma
• Glucocorticoid treatment > 6 months.
• Verified Allergy
• Read and speak Swedish

Exclusion criteria

• Smoking
• Current regular treatment with long-acting beta2-agonist
• Treatment with Singulair only or in combination with glucocorticoids
• Taking part in other research study
• Pregnancy or breast-feeding
• Unstable Asthma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

187 participants in 2 patient groups

Symptom-guided group

Sham Comparator group

Description:

Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.

Treatment:

Drug: Single corticosteroid inhalers and Singulair

FeNO-guided group

Active Comparator group

Description:

Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide

Treatment:

Drug: Single corticosteroid inhalers and Singulair